Sugi Predict

Sugi Predict / Compounds / SCHEMBL143763

SCHEMBL143763

SCHEMBL143763

O=C(NC1(C(=O)O)CC1)OCc1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CTSS P25774 5/20 0.57
▸ CTSL P07711 4/20 0.57
▸ CTSB P07858 3/20 0.57
▸ NPC1 O15118 2/20 0.51
▸ RAB9A P51151 2/20 0.51
▸ SMN1; SMN2 Q16637 2/20 0.50
▸ LMNA P02545 1/20 0.50
▸ CA12 O43570 2/20 0.49
▸ CA1 P00915 2/20 0.49
▸ CA2 P00918 2/20 0.49
▸ CA9 Q16790 2/20 0.49
▸ MGLL Q99685 1/20 0.49
▸ CTSK P43235 4/20 0.48
▸ ALDH1A1 P00352 4/20 0.48
▸ GAA P10253 1/20 0.48
▸ POLB P06746 1/20 0.48
▸ HTT P42858 1/20 0.48
▸ TP53 P04637 1/20 0.47
▸ MAPT P10636 1/20 0.47
▸ TSHR P16473 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4179836 0.94 CTSS (0.62) CTSSCTSLCTSBNPC1RAB9A
SCHEMBL1151498 0.94 CTSS (0.65) CTSSCTSLCTSBNPC1RAB9A
SCHEMBL8981223 0.92 CTSS (0.67) CTSSCTSLCTSBNPC1RAB9A
SCHEMBL8981228 0.92 CTSS (0.67) CTSSCTSLCTSBNPC1RAB9A
SCHEMBL1839379 0.92 CTSS (0.67) CTSSCTSLCTSBNPC1RAB9A
SCHEMBL8981271 0.92 CTSS (0.67) CTSSCTSLCTSBNPC1RAB9A
SCHEMBL8981148 0.92 CTSS (0.67) CTSSCTSLCTSBNPC1RAB9A
SCHEMBL7818404 0.90 TLR2 (0.53) CTSSCTSLCTSBNPC1RAB9A
SCHEMBL2704426 0.90 CTSS (0.52) CTSSCTSLCTSBNPC1RAB9A
SCHEMBL22041787 0.89 CTSS (0.49) CTSSCTSLCTSBNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 208 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4739685-A1 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS Janssen Pharmaceutica NV (BE) 2026-05-13 — — EP disclosed
US-20260062443-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMA INC (US) 2026-03-05 — — US disclosed
EP-4692057-A1 NOVEL B0AT1 INHIBITOR Mitsubishi Tanabe Pharma Corporation (JP) 2026-02-11 — — EP disclosed
US-20260001849-A1 NOVEL B0AT1 INHIBITOR MITSUBISHI TANABE PHARMA CORPORATION (JP) 2026-01-01 — — US disclosed
US-20250223291-A1 IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS INCYTE CORPORATION 2025-07-10 — — US disclosed
WO-2025056017-A1 FUSED BICYCLIC HETEROARYLS AS PARG INHIBITORS AND USES THEREOF ZAI LAB (SHANGHAI) CO., LTD. (CN) 2025-03-20 — — WO disclosed
WO-2025008061-A1 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS JANSSEN PHARMACEUTICA NV (BE) 2025-01-09 — — WO disclosed
US-12161625-B2 Substituted pyrrolizine compounds and uses thereof GILEAD SCIENCES, INC. (US) 2024-12-10 — — US disclosed
WO-2024210198-A1 NOVEL B0AT1 INHIBITOR 田辺三菱製薬株式会社 2024-10-10 — — WO disclosed
US-12084449-B2 Imidazotriazines and imidazopyrimidines as kinase inhibitors INCYTE HOLDINGS CORPORATION (US) 2024-09-10 — — US disclosed
US-6037356-A ANTICOAGULANTS; ANTIINFLAMMATORY AND ANTIARTHRITIC AGENTS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2000-03-14 — — US disclosed
WO-1999026926-A1 HETEROARYL AMINOGUANIDINES AND ALKOXYGUANIDINES AND THEIR USE AS PROTEASE INHIBITORS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 1999-06-03 — — WO disclosed
US-4822635-A Sweetening with L-aminodicarboxylic acid esters GENERAL FOODS CORPORATION (US) 1989-04-18 — — US disclosed
US-4788332-A ARTIFICAL SWEETENER GENERAL FOODS CORPORATION (US) 1988-11-29 — — US disclosed
US-4781927-A Sweetening with l-aminodicarboxylic acid esters GENERAL FOODS CORPORATION (US) 1988-11-01 — — US disclosed
US-4766246-A L-aminodicarboxylic acid esters GENERAL FOODS CORPORATION (US) 1988-08-23 — — US disclosed
US-4678674-A Sweetening with L-aminodicarboxylic acid amides GENERAL FOODS CORPORATION (US) 1987-07-07 — — US disclosed
EP-0199258-A2 L-Aminodicarboxylic acid amides and an edible composition containing same GENERAL FOODS CORPORATION (US) 1986-10-29 — — EP disclosed
EP-0199257-A2 L-Aminodicarboxylic acid esters and an edible composition containing same as sweeteners GENERAL FOODS CORPORATION (US) 1986-10-29 — — EP disclosed
US-4572799-A L-Aminodicarboxylic acid amides GENERAL FOODS CORPORATION (US) 1986-02-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260062443-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS C9, SSB, C1S CTSS 113/4885CTSL 514/4885CTSB 399/4885
US-20260001849-A1 NOVEL B0AT1 INHIBITOR BCAT1, BCAT2, BHMT CTSS 4816/4885CTSL 4565/4885CTSB 4842/4885
US-12161625-B2 Substituted pyrrolizine compounds and uses thereof HMBS, DHFR, HCCS CTSS 3150/4885CTSL 1324/4885CTSB 2201/4885
US-20250223291-A1 IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS ERBB2, MERTK, ABL1 CTSS 4020/4885CTSL 3481/4885CTSB 3690/4885
US-12084449-B2 Imidazotriazines and imidazopyrimidines as kinase inhibitors ERBB2, MERTK, ABL1 CTSS 4020/4885CTSL 3481/4885CTSB 3690/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.